Contact

• workRoom C214f BioDiscovery Institute-3
  University Park
  Nottingham
  NG7 2RD
  UK
• work0115 82 30993
• ruman.rahman@nottingham.ac.uk
• http://www.cbtrc.org/cbtrc/index.aspx

Biography

After graduating with a BSc in Genetics from the University of Edinburgh, Dr. Rahman completed a PhD in Molecular Biology at the Roslin Institute, University of Edinburgh under the supervision of Sir Ian Wilmut in 2007. He joined the Children's Brain Tumour Research Centre (CBTRC), University of Nottingham as a Post-Doctoral Research Associate in 2007, where a research highlight identified Nucleolin as a prognostic marker in paediatric ependymoma (Neuro-Oncology 10: 675-689, 2008).

After receiving the Nottingham Advanced Research Fellowship for the Faculty of Medicine in 2011, Dr. Rahman was appointed Assistant Professor at the University of Nottingham's School of Medicine in October 2013 and awarded the British Neuro-Oncology Society Young Investigator of the Year in 2014.

He currenty leads research programmes in neurosurgically-applied drug delivery, brain tumour heterogeneity and brain tumour metabolism as Associate Professor, with a grant portfolio of £6M since 2013. Key international collaborations include Johns Hopkins University, Mayo Clinic and University of Louvain, with a research highlight demonstrating a long-term survival benefit in orthotopic brain tumour models when combined chemotherapeutics are delivered at neurosurgery via a biodegradable paste (Clinical Cancer Research 25(16): 5094-5106, 2019).

His affiliation to professional bodies includes membership on the Evaluation Committee for the French National Institute of Health and Medical Research (INSERM) (2019-present), Society for Neuro-Oncology Conference Scientific Review Committee (2016-present), British Neuro-Oncology Society Research Sub-Committee (2018-present) and he is an editorial board member for Scientific Reports. He is currently Chair for the 'Children with Cancer UK' funded Children's Brain Tumour Drug Delivery Consortium which spans leading institutions across Europe and North America (including Johns Hopkins University and the National Cancer Institute) (2021-2023) and co-Chair of the British Neuro-Oncology Society Research Subcommittee (2021-2023)

Expertise Summary

Molecular and cellular neuro-oncology; biomaterial-based drug delivery.

Teaching Summary

Lecturing - 12 lectures (1 PhD, 7 BSc, 4MSc) across 7 modules.

University of Nottingham:

• Neuro-Oncological Application of Tissue Engineering Concepts - Tissue Engineering Course - CDT Regen Med (2017-present).

• Brain Cancer Future Medicines Seminar - BSc Biochemistry and Molecular Medicine, Year 3 Advanced Biochemistry of Cancer module (2016-present).
• Cancer Chemotherapy - Pre-Clinical/Clinical (BSc Biochemistry and Molecular Medicine, Year 3 Advanced Biochemistry of Cancer module (2015-present).
• Cancer Evolution I: Principles (BSc Biochemistry of Cancer C74CAN, Year 3 Advanced Biochemistry of Cancer module (2016-present).
• Cancer Evolution II: Application (BSc Biochemistry of Cancer C74CAN, Year 3 Advanced Biochemistry of Cancer module (2015-present).
• Biology of Metastasis - Adhesion Molecules and Cell-Cell/Matrix Interactions 1 (Migration) (MSc Oncology, A34C02/L/05 Tumour Physiology) (2015-present).
• Biology of Metastasis - Adhesion Molecules and Cell-Cell/Matrix Interactions 2 (Invasion) (MSc Oncology, A34C02/L/05 Tumour Physiology) (2015-present).
• Tumours of the Brain (BSc Graduate Entry Medicine BMBS) (2015 - present).
• Biomaterials and Cancer Therapeutics (BSc Medical Physiology and Therapeutics - 3^rd Year Cancer Biology Module) (2014 - present). (Setting, marking and moderating MCQ/SAQ for ~35 students).
• Localised drug delivery for brain cancer (BSc Medical Physiology and Therapeutics - 3^rd Year Cancer Biology Module) (2014 - present).
• Leukaemic Stem Cells (MSc. Stem Cell Technology) (2012-present).

Keele Medical School:

• Stem Cells in Cancer (MSc. 'Cell and Tissue Engineering' (2007-present).

Research Summary

My research group are broadly interested in two research themes: 1) Molecular Neuro-Oncology; 2) Brain tumour drug delivery.

1) Molecular Neuro-Oncology:

We have established dynaimc 3D brain tumour culture models using the NASA-developed Rotary Cell Culture System (RCCS). The molecular biology and genetics of brain tumour cells grown as 3D cultures better resembles the biology of the patients' tumour, when compared to traditional 2D cultures. We are now using this culture system to test the effectiveness of novel candidate anti-cancer drugs, thus avoiding the requirement to test such drugs in animals in the first instance.

We are also aiming to identify whether the biology of a brain tumour called glioblastoma (GBM), varies in different regions within each tumour (intratumour heterogeneity). Through a precise reading of the information carried in GBM DNA, we will spot 'errors' (mutations) that enable the cancer to survive. Similarly, by reading the information carried in GBM RNA, we will identify genes incorrectly switched on. A key goal will be to combine data on mutations and genes from different parts of the tumour to reveal which mutations are crucial to its survival. If these genes are identified, the proteins involved will also be known. Drugs that target these proteins will be tested on GBM cells grown in the RCCS and in mice with GBM tumours.

To complement our genome wide genetic mutation and gene expression analyses, my group is also developing a functional genomics approach to study GBM intra-tumour heterogeneity. Specifically we are conducting phospho-proteomics and metabolomics using advanced mass spectrometry methods.

2) Brain tumour drug delivery:

Current methods to deliver cancer chemotherapy drugs results in drugs reaching all parts of the body, causing the death of healthy cells. This also means that the amount of drug that reaches the tumour may not be enough to destroy it. We have evaluated a new drug delivery system which uses polymer microparticles to deliver drugs directly to the site of the tumour at the time of surgery, thereby targeting cancer cells that are often left behind and reducing drug-related side-effects throughout the body.The opportunity to deliver cancer drugs locally within the tumour resection cavity bypasses the blood-brain-barrier, targeting micro-deposits of neoplastic cells that remain following tumour resection. This has the potential to achieve a high effective dose locally whilst maintaining a low toxic dose systemically.

Selected Publications

• SMITH SJ, WARD JH, TAN C, GRUNDY RG and RAHMAN R, 2015. Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response. Oncotarget Oncotarget. 6(26), 22191-22205
• TAN, T.C.J., RAHMAN, R., JABER-HIJAZI, F., FELIX, D.A., CHEN, C., LOUIS, E.J. and ABOOBAKER, A., 2012. Telomere maintenance and telomerase activity are differentially regulated in asexual and sexual worms Proceedings of the National Academy of Sciences of the United States of America. 109(11), 4209-4214
• SMITH, S.J., WILSON, M., WARD, J.H., RAHMAN, C.V., PEET, A.C., MACARTHUR, D.C., ROSE, F.R.A.J., GRUNDY, R.G. and RAHMAN, R., 2012. Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition PLoS One. 7(12), e52335
• RAHMAN, R. and GRUNDY, R., 2011. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy International Journal of Cancer. 129(12), 2765-2774

• View all publications

PRIZES

British Neuro-Oncology Society Conference - Best Oral Presentation Jul 2015 (1^st).

School of Medicine Clinical Showcase - Best Poster Prize, Apr 2015 (1^st).

British Neuro-Oncology Society Young Investigator Award 2014 (* Highest national accolade in the field of neuro-oncology for basic or clinical scientists under the age of 35).http://blogs.nottingham.ac.uk/pressoffice/2014/07/09/national-award-for-innovative-nottinghamresearcher/

Genetics Society international writing competition, 2004 (1^st) (Rahman R. "The Stems of Cancer".Genetics Society Newsletter 2005; (52) 50-52).

INVITED TALKS

UK-Nordic Proteoglycan Conference (Uppsala, Sweden, 03/05/2023) - Title: Recapitulating post-surgical brain tumour microenvironments using human decellularized brain extracellular matrix.

(Invited Speaker) British-Iberian Bioelectronics Workshop (BIBio-e) (Instituto Superior Tecnico, Lisbon, Portugal, 17/02/23). Title: Harnessing bioelectronics as a new treatment modality for malignant brain cancer.

(Invited Plenary Speaker) IV International Congress in Health Sciences Research (University of Beira Interior, Covilha, Portugal, 13/02/23) - Title: Targeting glioblastoma infiltrative disease through a Darwinian lens.

Society for Image-Guided Neurointerventions (SIGN) Conference (Warwick Castle, 22/08/2022). Session: Bioscaffolds; Title: Polymer-based neurosurgically applied interstitial drug delivery for malignant glioma.

Department of Chemistry (Lancaster University, 27/07/2022) - Targeting glioblastoma residual disease using drug delivery systems applied at neurosurgery.

British Neuro-Oncology Society (Liverpool, 23/06/2022) - Session: Basic Science II. Title: Spatially resolved transcriptomics reveal unique defining molecular features of infiltrative tumour cells associated with glioblastoma recurrence.

Faculty of Science, Technology, Engineering and Mathematics Open University, School of Life, Health and Chemical Sciences, 07/06/2022) - Title: Characterisation and therapeutic targeting of glioblastoma infiltrative disease.

Cardiff University, School of Pharmacy & Pharmaceutical Sciences (Cardiff, 04/05/2022) - Targeting glioblastoma residual disease using drug delivery systems applied at neurosurgery.

Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) Consortium (Virtual (UK/US/Australian members, 05/04/2022) - Title: Pre-clinical models/Children's Brain Tumour Drug Delivery Consortium.

Leeds Institute of Medical Research (University of Leeds, 03/02/2022) - Title: Characterisation and therapeutic targeting of glioblastoma infiltrative disease.

Society for Neuro-Oncology (Boston, Massachusetts, 20/11/2021) - Session: Molecular Pathology; Title: Spatial-transcriptomics reveals unique molecular features of fluorescence-sorted 5-aminolevulinic acid+ infiltrative tumor cells associated with recurrence and poor survival in glioblastoma.

Children's Cancer & Leukaemia Group - Childhood Cancer Conference (Virtual) - (17/10/21) - Delivering chemotherapy to malignant childhood brain cancers using a biodegradable paste.

Society for Neuro-Oncology Paediatric Neuro-Oncology Conference (Washington DC/Virtual) - (10/11/2021) Moderator Session 2 - Synaptic signalling in paediatric brain tumours. (11/11/2021) Invited speaker and Session Chair - Session: Overcoming challenges to CNS therapeutic drug delivery for paediatric neuro-oncology - Title: Evolving strategies for efficacious drug penetration in paediatric brain tumours.

University of Santiago de Compostela, Centre for Research in Molecular Medicine and Chronic Diseases (Invited seminar) (30/10/2020) - Targeting malignant glioma infiltration.

Brain Tumour Charity (Invited Webinar) (21/10/2020) - Revealing hidden gene signatures for infiltrative glioblastoma using 5ALA.

University of Cambridge, Electrical Engineering Division (Invited seminar) (22/06/2020) - Title: Targeting glioblastoma residual disease using neurosurgically-applied drug delivery systems.

University of Nottingham Biochemistry Society Public Lecture - (Nottingham, 23/01/2020) - Title: Brain cancer through a Darwinian lens.

British Neuro-Oncology Society (London, 04/07/2019) - Session: Adult intrinsic tumours; clinical. Title: Neurosurgical delivery of the ADP ribose polymerase-1 inhibitor olaparib from a thermo-responsive biodegradable paste potentiates radiotherapy and prolongs survival.

Society for Image-Guided Neurointerventions (SIGN) Conference (Baltimore, 10/06/2019). Session: Opening Ceremony; Title: The Children's Brain Tumour Drug Delivery Consortium.

Society for Image-Guided Neurointerventions (SIGN) Conference (Baltimore, 11/06/2019). Session: Biomaterials and Nanotechnologies; Title: A neurosurgically-applied thermo-sensitive paste for the delivery of brain tumour chemo- and nano-therapies.

Children with Cancer UK 'Child and Teens/Young Adults' Conference (Westminster, London, 14/09/2018) - Title: Update on the Children's Brain Tumour Drug Delivery Consortium.

International Symposia for Pediatric Neuro-Oncology (Denver, Colorado, 02/07/2018) - Session: Drug Delivery; Title: The Children's Brain Tumour Drug Delivery Consortium.

Institute for NanoBio Technology, Johns Hopkins University, School of Medicine (Baltimore USA, 31/10/2017) - Multi-agent neurosurgical application of a chemotherapeutic paste in the treatment of malignant glioma.

Strathclyde Institute of Pharmacy and Biomedical Sciences (Glasgow, 06/10/2017) - Neurosurgical application of a polymeric paste for chemotherapy delivery in the treatment of malignant glioma.

Children with Cancer UK Precision Medicine in Childhood Cancer - (Newcastle, 18/09/2017) - Session: Introduction and Progress Update; Title: Children's Brain Tumour Drug Delivery Consortium.

Academy of Pharmaceutical Sciences - (University of Hertfordshire, 06/09/2017) - Session: Crossing the disciplinary divide for improved healthcare (sponsored by UK & Ireland Controlled Release Society; Title: Neurosurgical application of a polymeric paste for chemotherapy delivery in the treatment of malignant glioma.

British Science Association Public Lecture - (University of Nottingham, 20/07/2017) - Title: Darwin's Oncology Legacy.

Glioma Invasion Forum - (Piran, Slovenia, 25/04/2017) - Title: Genetic and metabolic signatures of the glioma margin.

Society for Neuro-Oncology (San Antonio, 20/11/2015) - Delineating intra-tumour metabolomic and phospho-proteomic heterogeneity in glioblastomas through advanced analytical methods.

Departments of Oncology and Stem Cell Research - (Imperial College London, 27/11/14). (Seminar) Glioma heterogeneity: from modeling to therapy.

British Neuro-Oncology Society (University of Liverpool, 03/07/2014) - Title: Glioma heterogeneity: from modeling to therapy. * Young Investigator Award Prize Lecture.

Society for Neuro-Oncology Basic and Translational Research (Fort Lauderdale, 16/05/2013) - Session: High Grade Glioma; Title: VEGF/FGF-dependent vasculogenic mimicry and tumor-derived angiogenic response in high grade glioma.

International Symposia for Pediatric Neuro-Oncology (Toronto, 26/06/2012) - Session: Advances in Neurosurgery; Title: Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix.

Society for Neuro-Oncology Basic and Translational Research (New Orleans, 19/05/2011) - Session: High Grade Glioma and Ependymoma; Title: Evaluating novel polymeric microparticle-based injectable matrices for local chemotherapeutic delivery.

British Neuro-Oncology Society (University of Cambridge, 01/07/2011) - Title: Evaluating novel polymeric microparticle-based injectable matrices for local chemotherapeutic delivery.

Past Research

I have studied the role of the telomere and telomerase pathways with respect to childhood brain cancer progression, particularly with respect to targeting telomerase as a potential mode of therapy. I have investigated the role of histone deacetylase inhibition using Trichostatin A in high grade paediatric tumours and have shown distinct telomerase inhibition associated with anti-proliferative and pro-apoptotic cellular effects. Additionally, I have evaluated the role of the G4 quadruplex ligand, RHPS4 in indirectly inhibiting telomerase by restricting access to the telomere. I am also interested in determining the contribution of dysregulated stem-like cells to childhood brain tumours and understanding mechanisms of resistance such cells may harbour; e.g.- cellular quiescence.

Future Research

Functional Genomic Characterisation of Intra-glioma Heterogeneity

To complement our genome wide genetic mutation and gene expression analyses, my group is also developing a functional genomics approach to study GBM intra-tumour heterogeneity. Specifically we are conducting phospho-proteomics and metabolomics using advanced mass spectrometry methods. We hypothesise that active proteins and metabolites predominant at the glioma invasive margin, represent clinically-relevant targets for therapy. We will develop orthotopic patient-derived xenografts using cells isolated from the invasive margin, thus representing a pre-clinical tailored pharmacological framework.

3D Cell Culture Models of Brain Tumours

We aim to assess whether these models are able to predict drug response in animals and in patients receiving identical therapy and use this system to test the anti-cancer effects of a new group of drugs called histone deacetylase inhibitors.

Local Drug Delivery for Brain Tumours

We aim to evaluate efficacy and neurotoxicity of our polymer-based drug delivery system in vivo. Additionally we will further develop the biomaterials approach to demonstrate greater flexibility in tailoring drug release profiles.

• HE, WENSHI, EDNEY, MAX K, PAINE, SIMON M L, GRIFFITHS, RIAN L, SCURR, DAVID J, RAHMAN, RUMAN and KIM, DONG-HYUN, 2023. Untargeted Metabolomic Characterization of Glioblastoma Intra-Tumor Heterogeneity Using OrbiSIMS. Analytical chemistry. 95(14), 5994-6001
• MURESAN, PAULA, MCCRORIE, PHOEBE, SMITH, FIONA, VASEY, CATHERINE, TARESCO, VINCENZO, SCURR, DAVID J., KERN, STEFANIE, SMITH, STUART, GERSHKOVICH, PAVEL, RAHMAN, RUMAN and MARLOW, MARIA, 2023. Development of nanoparticle loaded microneedles for drug delivery to a brain tumour resection site EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. 182, 53-61
• MARTINS, CLAUDIA, ARAUJO, MARCO, MALFANTI, ALESSIO, PACHECO, CATARINA, SMITH, STUART J. J., UCAKAR, BERNARD, RAHMAN, RUMAN, AYLOTT, JONATHAN W. W., PREAT, VERONIQUE and SARMENTO, BRUNO, 2023. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting SMALL. Feb28:e2300029,
• ADEKEYE, ADENIKE O., NEEDHAM, DAVID and RAHMAN, RUMAN, 2023. Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery PHARMACEUTICS. 15(2),
• MURESAN, PAULA, WOODHAMS, STEPHEN, SMITH, FIONA, TARESCO, VINCENZO, SHAH, JAYMIN, WONG, MEI, CHAPMAN, VICTORIA, SMITH, STUART, HATHWAY, GARETH, RAHMAN, RUMAN, GERSHKOVICH, PAVEL and MARLOW, MARIA, 2023. Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain. Nanomedicine : nanotechnology, biology, and medicine. 49, 102664
• RAHMAN, RUMAN, JANOWSKI, MIROSLAW, KILLICK-COLE, CLARE L., SINGLETON, WILLIAM G. B., CAMPBELL, EMMA, WALCZAK, PIOTR, KHATUA, SOUMEN, FALTINGS, LUKAS, SYMONS, MARC, SCHNEIDER, JULIA R., KWAN, KEVIN, BOOCKVAR, JOHN A., GILL, STEVEN S., OLIVEIRA, J. MIGUEL, BECCARIA, KEVIN, CARPENTIER, ALEXANDRE, CANNEY, MICHAEL, PEARL, MONICA, VEAL, GARETH J., MEIJER, LISETHE and WALKER, DAVID A., 2023. Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials CANCERS. 15(3),
• MOLONEY, C.; MEHRADNIA, F.; CAVANAGH, R. J.; IBRAHIM. A.; PEARCE, A. K.; RITCHIE, A. A.; CLARKE, P.; RAHMAN, R.; GRABOWSKA, A. M. AND ALEXANDER, C., 2023. Chain-extension in hyperbranched polymers alters tissue distribution and cytotoxicity profiles in orthotopic models of triple negative breast cancers Biomaterials Science. 11, 6545 - 6560
• ANDRIEUX, G, DAS, T, GRIFFIN, M, BOERRIES, M, HEIALND, D-H, SMITH, S.J and RAHMAN, R, 2023. Spatial transcriptomics reveals unique defining molecular features of 5-ALA-metabolizing cells associated with glioblastoma recurrence Genome Medicine. 15(1), 48
• JAIN, A, GOSLING, J, LIU, S, WANG, H, STONE, E.M, CHAKRABORTY, S, JAYARAMAN, P-S, PEREZ GARCIA, L, AMABILINO, D, SMITH, S.J, FROMHOLD, M, LONG, Y, TURYANSKA, L and RAHMAN, R, 2023. Wireless electrical-molecular quantum signalling for cancer cell apoptosis. Nature Nanotechnology.
• ALI ALAZZO, NURCAN GUMUS, PRATIK GURNANI, SNJEZANA STOLNIK, RUMAN RAHMAN, KEITH SPRIGGS and CAMERON ALEXANDER, 2022. Investigating histidinylated highly branched poly(lysine) for siRNA delivery J. Mater. Chem. B. 10(2), 236-246
• JOSHUA BRANTER, MARIA ESTEVEZ-CEBRERO, MOHAMMED DIKSIN, MICHAELA GRIFFIN, MARCOS CASTELLANOS URIBE, SEAN T. MAY, RUMAN RAHMAN, RICHARD GRUNDY, SURAJIT BASU and STUART J. SMITH, 2022. Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors International Journal of Molecular Sciences. 23(4), 1982
• PHOEBE MCCRORIE, JONATHAN ROWLINSON, DAVID J. SCURR, MARIA MARLOW and RUMAN RAHMAN, 2022. Detection of label-free drugs within brain tissue using Orbitrap secondary ion mass spectrometry as a complement to neuro-oncological drug delivery Pharmaceutics. 14(3), 571
• TOMI-ANDRINO, CLAUDIO, PANDELE, ALINA, WINZER, KLAUS, KING, JOHN, RAHMAN, RUMAN and KIM, DONG-HYUN, 2022. Metabolic modeling-based drug repurposing in Glioblastoma. Scientific reports. 12(1), 11189
• WOOD, JAMES, ABDELRAZIG, SALAH, EVSEEV, SERGEY, ORTORI, CATHERINE, CASTELLANOS-URIBE, MARCOS, MAY, SEAN T., BARRETT, DAVID A., DIKSIN, MOHAMMED, CHAKRABORTY, SAJIB, KIM, DONG-HYUN, GRUNDY, RICHARD G. and RAHMAN, RUMAN, 2022. Lipoprotein Deprivation Reveals a Cholesterol-Dependent Therapeutic Vulnerability in Diffuse Glioma Metabolism Cancers. 14(16),
• AKHIL JAIN, ISOBEL JOBSON, MICHAELA GRIFFIN, RUMAN RAHMAN, STUART SMITH and FRANKIE J. RAWSON, 2022. Electric field responsive nanotransducers for glioblastoma Bioelectronic Medicine.
• WILLIAMS, GARETH, CHAMBERS, DAVID, RAHMAN, RUMAN and MOLINA-HOLGADO, FRANCISCO, 2022. Transcription Profile and Pathway Analysis of the Endocannabinoid Receptor Inverse Agonist AM630 in the Core and Infiltrative Boundary of Human Glioblastoma Cells MOLECULES. 27(7),
• JAIN, AKHIL, TRINDADE, GUSTAVO, HICKS, JACQUELINE M, POTTS, JORDAN C, RAHMAN, RUMAN, HAGUE, RICHARD JM, AMABILINO, DAVID B, PÉREZ-GARCÍA, LLUÏSA and RAWSON, FRANKIE J, 2021. Modulating the Biological Function of Protein by Tailoring the Adsorption Orientation on Nanoparticles Journal of Colloid and Interface Science. 587, 150-161
• ROBINSON AJ, JAIN A, SHERMAN HG, HAGUE RJM, RAHMAN R and SANJUAN-ALBERTE P, 2021. Towards hijacking bioelectricity in cancer to develop new bioelectronic medicine Advanced Therapeutics. e2000248
• VASEY CE, CAVANAGH RJ, TARESCO V, MOLONEY C, SMITH SJ and RAHMAN R, 2021. Polymer pro-drug nanoparticles for sustained release of cytotoxic drugs evaluated in patient-derived GBM cell lines and in situ gelling formulations Pharmaceutics. 13(2), 208
• JORIS MEURS, DAVID J. SCURR, ANBARASU LOURDUSAMY, LISA C.D. STORER, GRUNDY, RG, ALEXANDER, MR and RAHMAN, R, 2021. Sequential Orbitrap Secondary Ion Mass Spectrometry and Liquid Extraction Surface Analysis-Tandem Mass Spectrometry-Based Metabolomics for Prediction of Brain Tumor Relapse from Sample-Limited Primary Tissue Archives Analytical Chemistry. 93(18), 6947–6954
• WOODWARD A, PANDELE A, ABDELRAZIG S, ORTORI CA, KHAN I, CASTELLANOS URIBE M, MAY S, BARRETT DA, GRUNDY RG and KIM D-H, 2021. Integrated metabolomics and transcriptomics analysis using dual-extraction of metabolites and RNA from brain cancer cells Metabolites. 11(4), 240
• RUSU, ALEXANDRA D, CORNHILL, ZOE E, COUTINO, BRENDA CANALES, URIBE, MARCOS CASTELLANOS, LOURDUSAMY, ANBARASU, MARKUS, ZSUZSA, MAY, SEAN T, RAHMAN, RUMAN and GEORGIOU, MARIOS, 2021. CG7379 and ING1 suppress cancer cell invasion by maintaining cell-cell junction integrity. Open biology. 11(9), 210077
• ROBINSON, ANDIE J., JAIN, AKHIL, RAHMAN, RUMAN, ABAYZEED, SIDAHMED, HAGUE, RICHARD J. M. and RAWSON, FRANKIE J., 2021. Impedimetric Characterization of Bipolar Nanoelectrodes with Cancer Cells ACS OMEGA. 6(44), 29495-29505
• CHIARA BASTIANCICH, ALESSIO MALFANTI, VERONIQUE PREAT and RUMAN RAHMAN, 2021. Rationally designed drug delivery systems for the local treatment of resected glioblastoma Advanced Drug Delivery Reviews. 177, 113951
• ALEX VASILEV, ROBA SOFI, STUART J. SMITH, RUMAN RAHMAN, ANJA G. TESCHEMACHER and SERGEY KASPAROV, 2021. Feasibility of Photodynamic Therapy for Glioblastoma with the Mitochondria-Targeted Photosensitizer Tetramethylrhodamine Methyl Ester (TMRM) Biomedicines. 9(10), 1453
• MORRIS, B, CURTIN, L, HAWKINS-DAARUD, A, HUBBARD, ME, RAHMAN, R, SMITH, SJ, AUER, D, TRAN, NL, HU, LS, SWANSON, KR and OWEN, MR, 2020. Identifying the spatial and temporal dynamics of molecularly-distinct glioblastoma sub-populations Mathematical Biosciences and Engineering. 17(5), 4905-4941
• SMITH, SJ, ROWLINSON, J, ESTEVEZ-CEBRERO, M, ONION, D, RITCHIE, A, WOOD, K, DIKSIN, M, LOURDUSAMY, A, GRUNDY, RG and RAHMAN, R, 2020. Metabolism based isolation of invasive glioblastoma cells with specific gene signatures and tumorigenic potential Neuro-Oncology Advances. (In Press.)
• COUTINO, BC, CORNHILL, Z, COUTO, A, MACK, NA, RUSU, AD, NAGARAJAN, U, FAN, YN, HADJICHARALAMBOUS, MR, URIBE, MC, BURROWS, A, LOURDUSAMY, A, RAHMAN, R and MAY, ST, 2020. A genetic analysis of tumour progression in Drosophila identifies the cohesion complex as a suppressor of individual and collective cell invasion iScience. 23(6), 101237
• YAO, A, STORR, SJ, ALHADYAN, K, RAHMAN, R, SMITH, SJ, GRUNDY, RG and PAINE, S, 2020. Thioredoxin system protein is associated with poor clinical outcome in adult and paediatric gliomas and medulloblastomas Molecular Neurobiology. 57(7), 2889-2901
• GRECO, C, TARESCO, V, PEARCE, AK, VASEY, CE, SMITH, SJ, RAHMAN, R, ALEXANDER, C, CAVANAGH, RJ and MUSUMECI, F, 2020. Development of pyrazolo[3,4-d]pyrimidine kinase inhibitors as potential clinical candidates for glioblastoma multiforme recurrences ACS Medicinal Chemistry Letters. 11, 657-663
• TARESCO, V, ABELHA, T, CAVANAGH, RJ, VASEY, CE, PEARCE, AK, SPRIGGS, KA, CLARKE, P, RITCHIE, A, MARTIN, SG, RAHMAN, R, GRABOWSKA, A and ASHFORD, M, 2020. Functionalized block co-polymer pro-drug nanoparticles with anti-cancer efficacy in 3D spheroids and in an orthotopic triple negative breast cancer model Advanced Therapeutics. 2000103
• VASILEV, A, SOFI, R, RAHMAN, R, SMITH, SJ and TESCHEMACHER, AG, 2020. Using light for therapy of glioblastoma multiforme Brain Sciences. 10(2), 75
• MCCRORIE P, VASEY C, SMITH SJ, MARLOW M and ALEXANDER C, 2020. Biomedical engineering approaches to enhance nanotherapeutic delivery for malignant glioma Journal of Controlled Release. 328, 917-931
• MCCRORIE P, MISTRY J, TARESCO V, LOVATO T, FAY M, RITCHIE, A, CLARKE P, SMITH SJ and MARLOW M, 2020. Etoposide and olaparib polymer-coated nanoparticles within a bio-adhesive sprayable hydrogel for post-surgical localised delivery to brain tumours European Journal of Biopharmaceutics and Pharmaceutics. 157, 108-2020
• WEI-HSIN H, SANCHEZ-GOMEZ P, GOMEZ-IBARLUCEA E, IVANOV D, RAHMAN R, GRABOWSKA A, CSABA N and ALEXANDER C, 2019. Structure-optimized interpolymer polyphosphazene complexes for effective gene delivery against glioblastoma Advanced Therapeutics. 2(3), 1800126
• LEE ST, RAHMAN R, MUTHOOSAMY K, MOHAMED NUH, SU, X and TAYYAB S, 2019. A robust assay for amplification-free and direct detection of telomerase activity in cell lysate using chimeric DNA-templated silver nanoclusters Microchimica Acta. 186(2), 81
• HOWARTH A, MADUREIRA P, LOCKWOOD G, STORER L, GRUNDY R, RAHMAN R and PILKINGTON G, 2019. Modulation of autophagy as a therapeutic approach for the treatment of paediatric high-grade glioma Brain Pathology. 29, 707-725
• SMITH SJ, TYLER BM, GOULD T, VEAL GJ, GORELICK N, ROWLINSON J, SERRA R, RITCHIE A, BERRY P, OTTO A, CHOI J, SKULI N, ESTEVEZ-CEBRERO M, SHAKESHEFF KM and BREM H, 2019. Overall survival in orthotopic malignant glioma is significantly prolonged by neurosurgical delivery of combined etoposide and temozolomide from a thermo-responsive biodegradable paste Clinical Cancer Research. 25(16), 5094-5106
• PHAN H, MINUT RI, MCCRORIE P, VASEY C, LARDER RR, KRUMINS E, MARLOW M, RAHMAN R, ALEXANDER C and TARESCO V, 2019. Role of self-assembly conditions and amphiphilic balance on nanoparticle formation of PEGylated-lactide copolymers in aqueous environments Journal of Polymer Science Part A Polymer Chemistry. 57, 1801-1810
• HAQUE F, VARLET P, PUNTONET J, STORER L, BOUNTALI A, RAHMAN R, GRILL J, CARCABOSO AM, JONES C, LAYFIELD R and GRUNDY RG, 2017. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta neuropathologica communications. 5(1), 45
• DIKSIN M, SMITH SJ and RAHMAN R, 2017. The Molecular and Phenotypic Basis of the Glioma Invasive Perivascular Niche. International journal of molecular sciences. 18(11),
• SMITH SJ, DIKSIN M, CHHAYA S, SAIRAM S, ESTEVEZ-CEBRERO MA and RAHMAN R, 2017. The Invasive Region of Glioblastoma Defined by 5ALA Guided Surgery Has an Altered Cancer Stem Cell Marker Profile Compared to Central Tumour. International journal of molecular sciences. 18(11),
• NAILOR,A, WALKER,DA and ET AL, 2016. Highlights of Children with Cancer UK’s Workshop on Drug Delivery in Paediatric Brain Tumours eCancer. 10, 630
• LOURDUSAMY A, RAHMAN R and GRUNDY RG, 2015. Expression alterations define unique molecular characteristics of spinal ependymomas. Oncotarget. 6(23), 19780-19791
• LOURDUSAMY A, RAHMAN R, SMITH SJ and GRUNDY RG, 2015. microRNA network analysis identifies miR-29 cluster as key regulator of LAMA2 in ependymoma. Acta Neuropathologica Communications. 3(26),
• SMITH SJ, WARD JH, TAN C, GRUNDY RG and RAHMAN R, 2015. Endothelial-like malignant glioma cells in dynamic three dimensional culture identifies a role for VEGF and FGFR in a tumor-derived angiogenic response. Oncotarget Oncotarget. 6(26), 22191-22205
• RAHMAN R, 2014. Biomaterial-based local drug delivery to brain tumors. Therapeutic delivery. 5(12), 1243-5
• LAGAH S, TAN I, RADHAKRISHNAN P, HIRST RA, WARD JH, O'CALLAGHAN C, SMITH SJ, STEVENS MFG, GRUNDY RG and RAHMAN R, 2014. RHPS4 G-quadruplex ligand induces anti-proliferative effects in brain tumor cells. PloS one. 9(1), e86187
• SMITH SJ, RAHMAN CV, CLARKE PA, RITCHIE AA, GOULD TW, WARD JH, SHAKESHEFF KM, GRUNDY RG and RAHMAN R, 2014. Surgical delivery of drug-releasing poly(lactic-co-glycolic acid) / poly(ethylene glycol) paste with in vivo effects against glioblastoma Annals of Royal College of Surgeons England. 96, 495-501
• RAHMAN CV, SMITH SJ, MORGAN PS, LANGMACK KA, CLARKE PA, RITCHIE AA, MACARTHUR DC, ROSE FR, SHAKESHEFF KM, GRUNDY RG and RUMAN RAHMAN, 2013. Adjuvant chemotherapy for brain tumors delivered via a novel intra-cavity moldable polymer matrix. PloS one. 8(10), e77435
• TAN, T.C.J., RAHMAN, R., JABER-HIJAZI, F., FELIX, D.A., CHEN, C., LOUIS, E.J. and ABOOBAKER, A., 2012. Telomere maintenance and telomerase activity are differentially regulated in asexual and sexual worms Proceedings of the National Academy of Sciences of the United States of America. 109(11), 4209-4214
• SMITH, S.J., WILSON, M., WARD, J.H., RAHMAN, C.V., PEET, A.C., MACARTHUR, D.C., ROSE, F.R.A.J., GRUNDY, R.G. and RAHMAN, R., 2012. Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition PLoS One. 7(12), e52335
• RAHMAN, R. and GRUNDY, R., 2011. Histone deacetylase inhibition as an anticancer telomerase-targeting strategy International Journal of Cancer. 129(12), 2765-2774
• HUSSEIN, D., PUNJARUK, W., STORER, L.C.D., SHAW, L., OTHMAN, R.T., PEET, A., MILLER, S., BANDOPADHYAY, G., HEATH, R., KUMARI, R., BOWMAN, K.J., BRAKER, P., RAHMAN, R., JONES, G.D.D. and WATSON, S., 2010. Pediatric brain tumor cancer stem cells: cell cycle dynamics, DNA repair, and etoposide extrusion Neuro-oncology. 13(1), 70-83
• RAHMAN, R., OSTESO-IBANEZ, T., HIRST, R.A., LEVESLEY, J., KILDAY, J.P., QUINN, S., PEET, A., O'CALLAGHAN, C., COYLE, B. and GRUNDY, R.G., 2010. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells Molecular Cancer Therapeutics. 9(9), 2568-2581
• RAHMAN R, SMITH S, RAHMAN C and GRUNDY R, 2010. Antiangiogenic Therapy And Mechanisms Of Tumor Resistance In Malignant Glioma. Journal Of Oncology. 2010, 251231
• KILDAY, JOHN-PAUL, RAHMAN, RUMAN, DYER, SARA, RIDLEY, LEE, LOWE, JAMES, COYLE, BETH and GRUNDY, RICHARD, 2009. Pediatric ependymoma: biological perspectives. Molecular cancer research : MCR. 7(6), 765-86
• RAHMAN R, HEATH R and GRUNDY R, 2009. Cellular Immortality In Brain Tumours: An Integration Of The Cancer Stem Cell Paradigm. Biochimica Et Biophysica Acta. 1792(4), 280-8
• RIDLEY, L., RAHMAN, R., BRUNDLER, M.A., ELLISON, D., LOWE, J., ROBSON, K., PREBBLE, E., LUCKETT, I., GILBERTSON, R.J., PARKES, S., RAND, V., COYLE, B. and GRUNDY, R.G., 2008. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma Neuro-Oncology. 10(5), 675-689
• RAHMAN, RUMAN, FORSYTH, NICHOLAS R and CUI, WEI, 2008. Telomeric 3'-overhang length is associated with the size of telomeres. Experimental Gerontology. 43(4), 258-65
• RAHMAN, RUMAN, MO, LING and CUI, WEI, 2006. Telomerase with mutated catalytic motifs has dominant negative effects on telomerase activity and inhibits cell growth. Biochemical and Biophysical Research Communications. 350(3), 796-802